Cargando…

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression

BACKGROUND AND METHODS: A double-blind, parallel-group, controlled study was performed to investigate if milnacipran was noninferior to paroxetine in terms of improvement in symptoms of depression in Japanese patients with major depressive disorders in a fixed-dose design. The efficacy and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kamijima, Kunitoshi, Hashimoto, Shinji, Nagayoshi, Eiichi, Koyama, Tsukasa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640608/ https://www.ncbi.nlm.nih.gov/pubmed/23650446 http://dx.doi.org/10.2147/NDT.S42915

Ejemplares similares

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression [Corrigendum]
Publicado: (2013)

Effect of high-dose milnacipran in patients with depression
por: Hayashi, Masatoshi, et al.
Publicado: (2007)

Milnacipran: recent findings in depression
por: Montgomery, Stuart, et al.
Publicado: (2010)

Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial
por: WANG, Zhiyang, et al.
Publicado: (2015)

A randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of venlafaxine extended release and a long-term extension study for patients with major depressive disorder in Japan
por: Higuchi, Teruhiko, et al.
Publicado: (2016)

Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice
por: Stasiuk, Weronika, et al.
Publicado: (2016)

Treatment of patients with comorbid depression and diabetes with metformin and milnacipran
por: Hofmann, Peter
Publicado: (2010)

Use of milnacipran in patients suffering from poststroke depression
por: Arora, Harish, et al.
Publicado: (2009)

Fibromyalgia, milnacipran and experimental pain modulation: study protocol for a double blind randomized controlled trial
por: Macian, Nicolas, et al.
Publicado: (2015)

Plasma levels of interleukin-6 and 3-methoxy-4-hydroxyphenylglycol and treatment with milnacipran in major depression
por: Yoshimura, Reiji, et al.
Publicado: (2022)

Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan
por: Higuchi, Teruhiko, et al.
Publicado: (2007)

Escitalopram versus paroxetine controlled release in major depressive disorder: a randomized trial
por: Kishi, Taro, et al.
Publicado: (2017)

Effect of triiodothyronine (T(3)) augmentation of acute milnacipran administration on monoamine levels: an in vivo microdialysis study in rats
por: Kitaichi, Yuji, et al.
Publicado: (2012)

Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study
por: Pickering, Gisèle, et al.
Publicado: (2018)

Effect of milnacipran on suicidality in patients with mild to moderate depressive disorder
por: Avedisova, Alla, et al.
Publicado: (2009)

Antidepressant therapy with milnacipran and venlafaxine
por: Mansuy, Lucilla
Publicado: (2010)

Milnacipran: a unique antidepressant?
por: Kasper, Siegfried, et al.
Publicado: (2010)

Milnacipran for the management of fibromyalgia syndrome
por: Ormseth, Michelle J, et al.
Publicado: (2010)

Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study
por: Olié, Jean-Pierre, et al.
Publicado: (2010)

Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study
por: Otsubo, Tempei, et al.
Publicado: (2018)

Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial
por: Kang, Ruiying, et al.
Publicado: (2015)

Marked effect of milnacipran combined with olanzapine for a delusional depressive patient
por: Sugawara, Yuka, et al.
Publicado: (2005)

White Matter Microstructure Alterations Associated With Paroxetine Treatment Response in Major Depression
por: Vieira, Rita, et al.
Publicado: (2021)

Paroxetine versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study
por: Woo, Young Sup, et al.
Publicado: (2017)

Effectiveness of paroxetine in the treatment of poststroke depression
por: Ma, Chen, et al.
Publicado: (2018)

Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies
por: Carboni, Lucia, et al.
Publicado: (2019)

Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression
por: Murasaki, Mitsukuni, et al.
Publicado: (2018)

Factors affecting discontinuation of initial treatment with paroxetine in panic disorder and major depressive disorder
por: Aoki, Akiko, et al.
Publicado: (2014)

Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence
por: Le Noury, Joanna, et al.
Publicado: (2015)

Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders
por: Saruwatari, Junji, et al.
Publicado: (2014)

Paroxetine in the treatment of recurrent brief depressive disorder
por: Prakash, Sathya, et al.
Publicado: (2013)

Role and rationale for the use of milnacipran in the management of fibromyalgia
por: Kranzler, Jay D, et al.
Publicado: (2010)

Evaluation of the Neurological Safety of Epidural Milnacipran in Rats
por: Lim, Seung Mo, et al.
Publicado: (2012)

Effect of milnacipran on body weight in patients with fibromyalgia
por: Arnold, Lesley M, et al.
Publicado: (2012)

Usefulness of milnacipran in treating phantom limb pain
por: Nagoshi, Yasuhide, et al.
Publicado: (2012)

Influence of serotonergic/noradrenergic gene polymorphisms on nausea and sweating induced by milnacipran in the treatment of depression
por: Higuchi, Hisashi, et al.
Publicado: (2009)

Trazodone effects on [(3)H]-paroxetine and α(2)-adrenoreceptors in platelets of patients with major depression
por: Marazziti, Donatella, et al.
Publicado: (2010)

Diabetes mellitus and comorbid depression: improvement of both diseases with milnacipran. A replication study (results of the Austrian Major Depression Diabetes Mellitus study group)
por: Abrahamian, Heidemarie, et al.
Publicado: (2012)

Efficacy of Hypericum extract WS(®) 5570 compared with paroxetine in patients with a moderate major depressive episode – a subgroup analysis
por: Seifritz, Erich, et al.
Publicado: (2016)

Paroxetine overdose
por: Gupta, Arun K., et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_o2n7ftpvf2lbcjfumqjkh1gua3